FDA Approves Dual-Drug Combo That Cuts Kidney Cancer Recurrence Risk by 28%
Belzutifan plus pembrolizumab wins FDA approval for high-risk kidney cancer after surgery, slashing recurrence risk in a landmark phase III trial.
Summary
The FDA has approved a two-drug combination — belzutifan and pembrolizumab — as a post-surgery treatment for adults with high-risk clear cell renal cell carcinoma (kidney cancer). The approval is based on the LITESPARK-022 phase III trial, which showed the combination reduced the risk of cancer returning or death by 28% compared to pembrolizumab alone. At two years, 80.7% of patients on the combo remained disease-free versus 73.7% on the single drug. This is the first adjuvant trial in kidney cancer to demonstrate a significant benefit of a combination therapy over an active immunotherapy alone, marking a meaningful shift in post-surgical standard of care for patients at elevated recurrence risk.
Detailed Summary
The FDA has granted approval to the combination of belzutifan (Welireg) and pembrolizumab (Keytruda) as adjuvant — meaning post-surgical — therapy for adults with clear cell renal cell carcinoma who face intermediate-high or high risk of cancer returning after kidney removal.
This approval is grounded in the LITESPARK-022 phase III randomized trial, which enrolled patients following nephrectomy or nephrectomy plus removal of metastatic lesions. The trial compared the two-drug combo against pembrolizumab plus placebo, representing an unusually rigorous comparison against an already-active immunotherapy rather than a simple placebo control.
The headline result: the belzutifan-pembrolizumab combination reduced the risk of disease recurrence or death by 28% (hazard ratio 0.72, P=0.0003). Two-year disease-free survival reached 80.7% in the combination arm versus 73.7% in the control arm — a clinically meaningful gap for a population at serious recurrence risk. Early overall survival data also trended in favor of the combination, though follow-up remains insufficient for definitive conclusions.
Belzutifan works by blocking HIF-2α, a protein that drives tumor growth in clear cell RCC, making it mechanistically complementary to pembrolizumab's immune checkpoint inhibition. This dual-pathway approach — targeting both the tumor's oxygen-sensing machinery and the immune brake — appears to add meaningful benefit beyond immunotherapy alone.
Side effects are a real consideration. Serious adverse events occurred in 30% of combination patients, including pneumonia, hypoxia, and acute kidney injury. Anemia and hypoxia are specific warnings for belzutifan, while pembrolizumab carries immune-mediated reaction risks. Patients and clinicians must weigh these risks against the recurrence reduction benefit. Overall, this approval represents a landmark advance for post-surgical kidney cancer management.
Key Findings
- Belzutifan plus pembrolizumab reduced kidney cancer recurrence or death risk by 28% versus pembrolizumab alone post-surgery.
- Two-year disease-free survival improved from 73.7% to 80.7% with the combination therapy in high-risk patients.
- This is the first phase III adjuvant kidney cancer trial to beat an active immunotherapy comparator with a combination approach.
- Early overall survival data trends favor the combination, though final data require longer follow-up.
- Serious adverse events occurred in 30% of combination patients, including pneumonia, hypoxia, and acute kidney injury.
Methodology
This is a news report from MedPage Today summarizing an FDA regulatory approval and the supporting phase III clinical trial (LITESPARK-022). The evidence basis is a randomized controlled trial with statistically significant disease-free survival data (P=0.0003). Overall survival data remain immature with only ~30% of required events recorded.
Study Limitations
Overall survival data are immature and cannot yet confirm a survival benefit beyond recurrence delay. The article is a brief news summary without full trial data; clinicians should review the complete LITESPARK-022 publication and FDA label. Long-term safety follow-up is ongoing and the benefit-risk profile for individual patients may vary.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.